Enhancing rAAV gene therapy manufacturing: Improving rAAV productivity & genome packaging through plasmid and cell engineering

The use of gene therapy products for the treatment of a large range of indications and as potential vaccines in the clinic shows great promise but producing high titre viral vectors and manufacturing at scale remains a challenge and contributes to the cost of these therapies.
At the University of Kent we have used HET293 cells to produce viral…